|
1
|
Søreide K, Sandvik OM, Søreide JA, Giljaca
V, Jureckova A and Bulusu VR: Global epidemiology of
gastrointestinal stromal tumours (GIST): A systematic review of
population-based cohort studies. Cancer Epidemiol. 40:39–46. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Du CY, Zhou Y, Song C, Wang YP, Jie ZG, He
YL, Liang XB, Cao H, Yan ZS and Shi YQ: Is there a role of surgery
in patients with recurrent or metastatic gastrointestinal stromal
tumours responding to imatinib: A prospective randomised trial in
China. Eur J Cancer. 50:1772–1778. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
ESMO/European Sarcoma Network Working
Group, . Gastrointestinal stromal tumours: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol.
25:(Suppl 3). iii21–iii26. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Corless CL, Fletcher JA and Heinrich MC:
Biology of gastrointestinal stromal tumors. J Clin Oncol.
22:3813–3825. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Barnett CM, Corless CL and Heinrich MC:
Gastrointestinal stromal tumors: Molecular markers and genetic
subtypes. Hematol Oncol Clin North Am. 27:871–888. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Corless CL, Barnett CM and Heinrich MC:
Gastrointestinal stromal tumours: Origin and molecular oncology.
Nat Rev Cancer. 11:865–878. 2011.PubMed/NCBI
|
|
7
|
Iorio N, Sawaya RA and Friedenberg FK:
Review article: The biology, diagnosis and management of
gastrointestinal stromal tumours. Aliment Pharmacol Ther.
39:1376–1386. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Joensuu H, Fletcher C, Dimitrijevic S,
Silberman S, Roberts P and Demetri G: Management of malignant
gastrointestinal stromal tumors. Lancet Oncol. 3:655–664. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Miettinen M, Furlong M, Sarlomo-Rikala M,
Burke A, Sobin LH and Lasota J: Gastrointestinal stromal tumors,
intramural leiomyomas, and leiomyosarcomas in the rectum and anus:
A clinicopathologic, immunohistochemical, and molecular genetic
study of 144 cases. Am J Surg Pathol. 25:1121–1133. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Day E, Waters B, Spiegel K, Alnadaf T,
Manley PW, Buchdunger E, Walker C and Jarai G: Inhibition of
collagen-induced discoidin domain receptor 1 and 2 activation by
imatinib, nilotinib and dasatinib. Eur J Pharmacol. 599:44–53.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Peng B, Lloyd P and Schran H: Clinical
pharmacokinetics of imatinib. Clin Pharmacokinet. 44:879–894. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
DeMatteo RP, Lewis JJ, Leung D, Mudan SS,
Woodruff JM and Brennan MF: Two hundred gastrointestinal stromal
tumors: Recurrence patterns and prognostic factors for survival.
Ann Surg. 231:51–58. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Blanke CD, Demetri GD, von Mehren M,
Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, Fletcher CD,
Roberts PJ, Heinz D, et al: Long-term results from a randomized
phase II trial of standard-versus higher-dose imatinib mesylate for
patients with unresectable or metastatic gastrointestinal stromal
tumors expressing KIT. J Clin Oncol. 26:620–625. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
von Mehren M, Heinrich MC, Joensuu H,
Blanke CD, Wehrle E and Demetri GD: Follow-up results after 9 years
(yrs) of the ongoing, phase II B2222 trial of imatinib mesylate
(IM) in patients (pts) with metastatic or unresectable KIT+
gastrointestinal stromal tumors (GIST). J Clin Oncol. 29:(Suppl):
Abstract 10016. 2011.PubMed/NCBI
|
|
15
|
Demetri GD, von Mehren M, Blanke CD, Van
den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA,
Singer S, Janicek M, et al: Efficacy and safety of imatinib
mesylate in advanced gastrointestinal stromal tumors. N Engl J Med.
347:472–480. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Blanke CD, Rankin C, Demetri GD, Ryan CW,
von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki
RG, et al: Phase III randomized, intergroup trial assessing
imatinib mesylate at two dose levels in patients with unresectable
or metastatic gastrointestinal stromal tumors expressing the kit
receptor tyrosine kinase: S0033. J Clin Oncol. 26:626–632. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Blanke CD, Rankin C, Benjamin R, Raymond
AK, Heinrich MC, Fletcher CDM, Crowley J, Borden EC, Demetri GD and
Baker LH: Long-term survival on S0033-a phase III randomized,
intergroup trial assessing imatinib mesylate at two dose levels in
patients with unresectable or metastatic gastrointestinal stromal
tumors (GISTs). Eur J Cancer. 47:(Suppl 1): Abstract 9404. 2011.
View Article : Google Scholar
|
|
18
|
Corless CL and Heinrich MC: Molecular
pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol.
3:557–586. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wardelmann E, Merkelbach-Bruse S, Pauls K,
Thomas N, Schildhaus HU, Heinicke T, Speidel N, Pietsch T, Buettner
R, Pink D, et al: Polyclonal evolution of multiple secondary KIT
mutations in gastrointestinal stromal tumors under treatment with
imatinib mesylate. Clin Cancer Res. 12:1743–1749. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Serrano C and George S: Recent advances in
the treatment of gastrointestinal stromal tumors. Ther Adv Med
Oncol. 6:115–127. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Patrikidou A, Chabaud S, Ray-Coquard I,
Bui BN, Adenis A, Rios M, Bertucci F, Duffaud F, Chevreau C,
Cupissol D, et al: French Sarcoma Group: Influence of imatinib
interruption and rechallenge on the residual disease in patients
with advanced GIST: Results of the BFR14 prospective French Sarcoma
Group randomised, phase III trial. Ann Oncol. 24:1087–1093. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Blay JY and Rutkowski P: Adherence to
imatinib therapy in patients with gastrointestinal stromal tumors.
Cancer Treat Rev. 40:242–247. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Patel S: Managing progressive disease in
patients with GIST: Factors to consider besides acquired secondary
tyrosine kinase inhibitor resistance. Cancer Treat Rev. 38:467–472.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li J, Gong JF, Li J, Gao J, Sun NP and
Shen L: Efficacy of imatinib dose escalation in Chinese
gastrointestinal stromal tumor patients. World J Gastroenterol.
18:698–703. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Demetri GD, Reichardt P, Kang YK, Blay JY,
Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M,
Joensuu H, et al: Efficacy and safety of regorafenib for advanced
gastrointestinal stromal tumors after failure of imatinib and
sunitinib (GRID): An international, multicentre, randomised,
placebo-controlled, phase 3 trial. Lancet. 381:295–302. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kang YK, Ryu MH, Yoo C, Ryoo BY, Kim HJ,
Lee JJ, Nam BH, Ramaiya N, Jagannathan J and Demetri GD: Resumption
of imatinib to control metastatic or unresectable gastrointestinal
stromal tumours after failure of imatinib and sunitinib (RIGHT): A
randomised, placebo-controlled, phase 3 trial. Lancet Oncol.
14:1175–1182. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Park SJ, Ryu MH, Ryoo BY, Park YS, Sohn
BS, Kim HJ, Kim CW, Kim KH, Yu CS, Yook JH, et al: The role of
surgical resection following imatinib treatment in patients with
recurrent or metastatic gastrointestinal stromal tumors: Results of
propensity score analyses. Ann Surg Oncol. 21:4211–4217. 2014.
View Article : Google Scholar : PubMed/NCBI
|
